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ABSTRACT  
Background. To identify predictors of changes in functional hepatic volumes after portal 
vein embolization (PVE) before hepatectomy, we examined the relationship between 
hepatic functional parameters and changes in functional volume of the embolized and 
non-embolized liver based on a previous volumetric analysis.  
Patients and Methods. Subjects were 24 patients who underwent PVE, which was 
performed through the trans-ileocolic vein (n=4) or by percutaneous transhepatic 
puncture (n=20). The RI liver volume parameter was measured by liver scintigraphy with 
technetium-99m galactosyl human serum albumin (99mTc-GSA). CT volume parameter 
was also measured. 
Results. Significant atrophy of the embolized liver and hypertrophy of the 
non-embolized liver  (change of 72±108 cm3 and 111±91cm3, respectively) (change of 
7.8%) was observed after PVE. The change in these RI volume parameters (change of 
173±175cm3 and 145±137 cm3 , respectively) (16.5%) was significantly greater than CT 
volume parameters (p<0.01). CT vol and RI vol in the embolized and non-embolized liver 
were well correlated (r=0.75 and 0.69, respectively). However, the correlation between 
CT and RI volume parameters in the embolized and non-embolized liver after PVE was 
very weak (r=0.17 and 0.03, respectively). Only alkaline phosphatase level correlated 
negatively with atrophic CT volume parameter of the embolized liver (r=-0.455, p<0.05). 
When compared with CT volume parameter, more parameters were significantly 
correlated with changes of RI volume parameter in the embolized liver: pre-PVE 
pressure; ICGR15; and serum levels of hyaluronate, total bilirubin, albumin, and alkaline 
phosphatase. Only platelet count was significantly correlated with hypertrophy of the 
non-embolized liver.  
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Conclusion. RI volume parameter might more accurately reflect functional changes in 
the embolized liver and non-embolized liver than CT volume parameter. Correlated 
parameters might allow us to predict the functional effect of PVE. 
 
Key Words: Liver resection; portal vein embolization; functional liver volume; liver 
functional reserve; platelet count 
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INTRODUCTION 
The risk of postoperative hepatic failure or related death in patients who undergo 
major hepatectomy has markedly decreased recently with adequate preoperative 
assessment of hepatic function, precise estimation of liver volume, and improvements in 
perioperative management [1, 2]. However, the risk of posthepatectomy hepatic failure 
after extensive resection for hilar bile duct carcinoma or liver malignancies with 
co-existing impaired liver function remains a problem [3, 4]. In patients undergoing right 
hepatectomy or more extensive liver resection, preoperative portal vein embolization 
(PVE), which allows a smaller hepatic resection and induces hypertrophy of the remnant 
liver, is a useful option. It can extend the operative indications and improve 
post-hepatectomy prognosis [5, 6]. The clinical significance of PVE has been well 
recognized, and it is often incorporated into the preoperative preparation for major 
hepatectomy  [5-8].  
When PVE is scheduled, it is worthwhile  to predict the degree of hypertrophy of 
non-embolized liver. Better regeneration of non-embolized liver after PVE and 
hepatectomy may prevent post-hepatectomy complications. Predictors of changes in the 
embolized and non-embolized liver have been reported [9, 10]; however, these have not 
yet been widely clarified. Our previous examination of predictors of liver volume change 
after PVE found that alkaline phosphatase (ALP) level was negatively correlated with 
atrophy of the embolized lobe, and that platelet count was positively correlated with 
hypertrophy of the non-embolized lobe [11]. However, the clinical significance of these 
parameters was not obvious.  
Liver volume is usually evaluated by computed tomography (CT); however, real 
functional liver volume may differ from morphological volume in the diseased liver, such 
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as in obstructive jaundice [12, 13]. Asialoglycoprotein receptors on hepatocytes reflect 
functional liver cells [14]. A reliable test assessing hepatic functional reserve, 
technetium-99m galactosyl human serum albumin (99mTc-GSA) scintigraphy, has been 
used in patients with liver disease and this type of scintigraphy reflects asialoglycoprotein 
receptors of living liver cells [15]. 99mTc-GSA scintigraphy can provide useful 
information concerning functional liver volume in any part of the liver [16], and this is 
clinically useful to determine the appropriate hepatectomy. This examination reflects the 
effect of PVE better than CT volumetry [17]. We have hypothesized that the functional 
volume might more closely reflect a correlation with predictive parameters for PVE 
effect in comparison with morphological volume by CT. Therefore, we have continued to 
examine both morphological and functional hepatic volume before and after PVE to 
clarify our hypothesis in the present study, as a follow-up to our previous report [11]. 
In the present study, we examined the relationships between liver functional 
parameters and changes in functional liver volume using 99mTc-GSA scintigraphy of the 
embolized and non-embolized liver after PVE as a preliminary study. We hypothesized 
that there would be more parameters associated with functional volume than with 
morphological volume. We hope that identification of such parameters can help us 
improve the clinical strategy for patients undergoing major hepatectomy. 
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PATIENTS AND METHODS 
Patients 
Forty-four patients underwent PVE in the Division of Surgical Oncology, Department 
of Translational Medical Sciences, Nagasaki University Graduate School of Biomedical 
Sciences (NUGSBS) between January 1995 and November 2009. Functional liver 
volume began to be examined in 24 patients (55%) in 1999, and these were the subjects of 
the present study. To examine the new factor of functional hepatic volume, data in 13 
patients analyzed in the previous report [11] were included in the present analysis as a 
follow-up report. Participants were 15 men and 9 women with a mean age (SD) of 
63.712.3 years (range, 39-79 years). Liver diseases were hepatocellular carcinoma 
(n=5), intrahepatic cholangiocarcinoma (n=2), metastatic liver carcinoma (n=3), 
gallbladder carcinoma (n=4), and bile duct carcinoma (n=10). The background hepatic 
condition  was normal liver function (n=12), chronic viral liver disease (n=5; caused by 
hepatitis B virus [n=3] or hepatitis C virus [n=2], including 2 with cirrhosis) and 
obstructive jaundice (n=7).  
In our hospital, the volume of the liver to be resected is determined preoperatively 
based on the indocyanine green retention rate at 15 minutes (ICGR15) using Takasaki’s 
formula [18].The estimated resected liver volume, excluding tumor volume (cm3), is 
measured by CT volumetry [12]. Essentially, in cases where the permitted resected 
volume of the liver is greater than the estimated resected volume of the liver, the planned 
hepatectomy is performed. In cases where the permitted resected volume is less than the 
estimated volume, or the estimated volume is over 65% in normal liver and over 50% in 
cirrhosis, preoperative PVE is selected [19]. Liver activity at 15 minutes (LHL15) in 
99mTc-GSA scintigraphy was performed pre-operatively with the ICGR15 [20]. 
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Hemihepatectomy was performed in 9 patients and more extensive hepatectomy in 9 
(including hepato-pancreato-duodenectomy in 3). Hepatectomy was abandoned during 
laparotomy in 6 patients because of advanced disease such as peritoneal carcinomatosis.  
The study design was approved by the Ethics Review Board of our institution and 
written consent for PVE was obtained from each subject. The present analysis was a 
retrospective study. Data were retrieved from both anesthetic and patient charts plus the 
NUGSBS database, for the duration of the initial hospitalization following hepatectomy. 
 
Technique of portal vein embolization and evaluation 
The two approaches to the right portal vein were direct catheterization of the ileocolic 
vein (n=4) and percutaneous transhepatic puncture (n=20) [5, 7]. Between 1999 and 2007, 
substances used for embolization in our series included 1 g of absorbable gelatin sponge 
powder (Gelfoam®; Upjohn, Kalamazoo, MI) and 5,000 units (5 ml) of liquid thrombin 
(Sankyou Co., Tokyo, Japan) mixed in the contrast media, or iodized oil (Lipiodol; 
Savage Lab., Melville, NY) mixed with gelatin (Sponzel; Astellas Pharma, Inc., Tokyo, 
Japan). Since 2008, an liquid embolization material, 5% of ethanolamine oleate 
iopamiodole (EOI; Oldamin; Takeda Pharma, Osaka, Japan) was mainly used for 
embolization. Permanent embolization materials or coils were not used. Embolization 
was completed when the entire right portal vein was completely occluded. At 14 days 
after PVE, the hepatic volumes of the non-embolized lobe and embolized lobe (lobe to be 
resected) were reassessed by CT volumetry (CT vol) and 99mTc-GSA scintigraphy (RI 
volume parameter) [21]. Scheduled hepatectomy was performed at 21-28 days after PVE. 
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Compared parameters 
Clinicopathological parameters (age, gender, background liver disease), laboratory 
data (portal pressure; serum levels of hyaluronic acid (HA), bilirubin, alanine 
transaminase, total cholesterol, and albumin; prothrombin activity; platelet count; 
ICGR15, LHL15 on 99mTc-GSA scintigraphy; and substance of embolization were 
examined and compared in relation to changes of hepatic volume (CT and RI volume 
parameters). Serum HA level was assayed using the sandwich binding protein assay by 
SRL, Inc. (Tokyo, Japan) and the manufacturer’s normal value of less than 50 ng/ml was 
used [22]. Portal pressure before and immediately after PVE was measured by 
cannulation of the portal trunk during PVE. A dose of 0.5 mg ICG/kg body weight was 
injected intravenously and the 15-minute retention rate was measure by a photopiece 
applied to the fingertip (Sumitomo Electric, Tokyo, Japan) without blood sampling. 
 
Volumetric measurement by CT and 99mTc-GSA liver scintigraphy 
Morphological volume was measured using contrast computed tomography (CT volume 
parameter) [5, 12]. Serial axial scans were taken at 3 mm intervals by a 16-row 
multidetector CT scanner, and the hepatic volume of areas without tumors and large 
vessels in each liver region was 3-dimensionally measured using Workstation software 
(Ziostation version 1.1, Ziosoft Inc., Tokyo, Japan) as in Fig. 1a. Regarding 99mTc-GSA 
liver scintigraphy, all patients received 3 mg (185 MBq) of 99mTc-GSA (Nihon 
Medi-Physics, Nishinomiya, Japan) as a bolus dose into an antecubital vein. Images were 
obtained with a large field-of-view gamma camera (Picker PRISM-2000, Picker Prism 
International, Cleveland, OH) equipped with a high resolution, parallel-hole collimator 
centered on the liver and the precordium. Sequential abdominal digital images (128x128 
Revised-May 5-Nanashima et al., Page 9  
matrixes) were acquired to an on-line nuclear data processor (OdysseyTM Series, Picker 
Prism International) at 30 sec/frame for the first 16 minutes after the injection. Hepatic 
single-photon emission CT (SPECT) images were acquired by axial or coronary imaging 
after the dynamic study (Fig. 1b) [23]. Each set of projection data was obtained in a 
128x128 matrix, and 120 projections (3 degrees/step,  15 sec/projection) were acquired. A 
Butterworth filter was used as the pre-reconstruction filter, and final reconstruction was 
performed with a Ramp filter. Attenuation correction was performed with Chang’s 
method [24], and a value of 0.09 cm-1 was used as the effective attenuation correction 
coefficient. Transaxial SPECT images were reconstructed with 3.91 mm-slice thickness. 
The border between the right and left lobe of the liver was manually determined through 
the gallbladder bed and inferior vena cava. A cut-off level was set at 40% of the maximum 
counts of the liver because the result closest to the actual volume was obtained in a 
phantom study (not yet published). The composite image of CT and 99mTc-GSA was 
constructed by Ziostation.  
 
Statistical analysis 
All continuous data are expressed as mean  SD. Data for different groups were 
compared using one-way analysis of variance (ANOVA). Chi-square test was used for 
comparison of categorical variables. Differences between groups were analyzed by 
Fisher’s exact test or Scheffe’s multiple comparison test. Correlations between two 
parameters were examined by calculating the Pearson’s correlation coefficient. The 95% 
confidence intervals for each correlation were calculated. A two-tailed P value < 0.05 was 
considered significant. StatView Software for Windows, version 5.0 (SAS Institute, Inc., 
Cary, NC) was used for all statistical analyses. 
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RESULTS 
Results of PVE 
No serious morbidity or mortality was recorded during the 3 weeks after PVE.  
CT volume parameters 
CT volume parameters estimated before surgery were as follows: total hepatic 
volume, 1080±240 cm3 (range: 745-1582 cm3); right hemi-liver volume, 714±200 cm3 
(range: 400-1095 cm3); and left hemi-liver volume, 358±102 cm3 (range: 176-609 cm3). 
The proportion of the total liver occupied by the right hemi-liver  estimated before 
surgery was 66±7% (range: 50-78%). Total hepatic volume after PVE (1093±227 cm3) 
did not differ significantly from that before PVE (p=0.65). After PVE, the volumes of the 
embolized and non-embolized liver were 623±207 cm3 (a decrease of 7.8%, –72±108 
cm3) and 470±130 cm3 (an increase of 7.8%, +111±91 cm3), respectively. Both the 
decrease in the volume of the embolized right liver and the increase in the volume of 
non-embolized left liver were significant (p<0.001). 
RI volume parameters 
RI volume parameters estimated before surgery were: total hepatic volume, 968±231 
cm3 (range: 804-1219 cm3); right hemi-liver volume, 613±214 cm3 (range: 132-1017 
cm3); and left hemi-liver volume, 355±124 cm3 (range: 202-672 cm3). RI volume 
parameters did not differ significantly from CT volume parameters. The proportion of the 
total liver occupied by the right hemi-liver estimated before surgery was 63±9% (range: 
21-79%). Total hepatic volume after PVE (940±214 cm3) did not differ significantly from 
that before PVE (p=0.78). After PVE, the volumes of the embolized and non-embolized 
liver were 440±205 cm3 (a decrease of 16.5%, −173±175 cm3) and 500±209 cm3 (an 
increase of 16.5%, +145±137 cm3), respectively. Both the decrease in the volume of the 
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embolized right liver and the increase in the volume of non-embolized left liver were 
significant (p<0.001).  
Comparison of CT and RI volume parameters 
Changes in volume parameters in the embolized and non-embolized liver were 
significantly higher for RI than for CT (p=0.003). Before PVE, a significant positive 
correlation between CT and RI volume parameters in the embolized and non-embolized 
liver was observed (r=0.75 and 0.69, respectively)(p<0.001) in the embolized and 
non-embolized liver. The 95% confidence intervals for each correlation was ranged 
between 0.499 and 0.886, and between 0.399 and 0.856, respectively. The correlation 
between CT and RI volume parameters was also significant in the embolized and 
non-embolized liver after PVE (r=0.69 and 0.51, respectively)(p=0.01). The 95% 
confidence intervals for each correlation was ranged between 0.397 and 0.855, and 
between 0.136 and 0.758, respectively. However, the correlation between changes in CT 
and RI volume parameters after PVE was not significant in either the embolized or 
non-embolized liver (r=−0.17 and −0.03, respectively)( p=0.36 and p=0.88, respectively). 
The 95% confidence intervals for each correlation was ranged between -0.537and 0.250, 
and between -0.428 and 0.378, respectively. 
 
Parameters associated with changes in liver volume 
Tables 1-3 show the relationship between hepatic volume and various clinical and 
laboratory parameters. Gender, background liver disease, and embolization substance 
were not significantly related to changes in hepatic volumes  after PVE, although changes 
of embolized liver volumes by CT and RI tended to be lower in cirrhosis than in other 
conditions. With respect to CT volume parameters, only ALP level was negatively 
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correlated with changes in the embolized (decreased) liver and only platelet count was 
associated with changes in the non-embolized (hypertrophic) liver (Table 2). On the other 
hand, with respect to RI volume, pre-PVE portal pressure; ICGR15; and serum levels of 
hyaluronic acid, total bilirubin, albumin, and ALP were significantly correlated with 
changes in the embolized liver, and platelet count was significantly correlated with 
increased volume of the non-embolized liver.  
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DISCUSSION 
Following PVE, previous reports have shown that the morphological volumes of the 
embolized and non-embolized liver change dramatically and rapidly [9, 25, 26], and our 
present study confirmed similar results [21, 27]. PVE is an established strategy for major 
hepatectomy in patients with impaired liver function, hilar bile duct carcinoma, or 
hepatocellular carcinoma [3-11]. Atrophy of the embolized lobe and hypertrophy of the 
non-embolized lobe were also observed even in the impaired liver in the present study as 
well as our previous preliminary studies [21, 27]. Our present results showed that changes 
in hepatic volumes did not differ significantly between normal and impaired liver, 
although changes of liver volume tended to be lower in liver cirrhosis. Therefore, PVE 
can be applied for even patients with diseased liver as previously reported [26, 28]. 
Before performing PVE, surgeons would like to predict the extent of changes in the right 
and left lobes as a result of PVE. Based on our results and those of others, a 9-30% 
increase in the volume of the non-embolized lobe (estimated remnant liver) can be 
expected [6, 25, 26]. This supports the findings of Manizate et al., who emphasized the 
significance of PVE as a stress test of the liver’s regenerative capacity [30]. 
In patients who undergo PVE, background liver status varies, as in the present series, 
because PVE is often influenced by impaired liver function. In such heterogeneous 
subjects, we usually determine the indications for hepatectomy based on common criteria. 
Functional evaluation in each liver area is used to determine treatment. Embolization 
substances changed during the period of this study; however, complete embolization of 
the targeted portal vein was accomplished in the present series. In the present preliminary 
study, we focused on the changes of functional volume after PVE in comparison with 
morphological volume detected by CT. After PVE, the function of each liver cell may 
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deteriorate. Our previous study clarified a discrepancy between morphological volume 
and functional volume assessed by 99mTc-GSA in cases with biliary obstruction [31]. The 
present results showed a significant difference between both volumes after PVE. We 
previously examined predictive factors for the degree of change of hepatic morphological 
volume after PVE [11]; however, few parameters were correlated with these 
morphological volumes. Based on the results using 99mTc-GSA, we hypothesized that 
more correlated parameters could be clarified by conducting a comparison with 
functional liver volume because functional liver volume changed more dramatically than 
morphological liver volume, and because functional liver volume better reflects the 
extent of impairment caused by biliary obstruction or reduced hepatic perfusion. [7, 13, 
21, 32, 33] As expected, more correlated preoperative parameters could be observed in 
the present study: pre-PVE portal pressure, serum hyaluronic acid level, ICGR15, total 
bilirubin, albumin level and ALP level were correlated with decreased liver volume, and 
bilirubin level and platelet count were correlated with hypertrophic liver volume. Portal 
hypertension reflects impairment of the liver secondary to chronic hepatitis, and it 
increases operative risk [34, 35]. In portal hypertension, there may already be impairment 
of the hepatocellular function or a decrease of functional liver cell mass resulting from 
chronic endothelial-cellular damage. Hence the atrophic response in liver with portal 
hypertension would be lower than in normal portal pressure [36]. After PVE, portal 
pressure dramatically increased in some cases and, therefore, we expected that increased 
portal pressure was correlated with changes of hepatic volumes after PVE. However, 
post-PVE pressure and increased portal pressure were not correlated with changes of 
functional volume in the present study. Jensen et al. reported that acute portal 
hypertension did not induce severe hypoxic damage in the functional part of the liver [37] 
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and, therefore, hepatic function could be preserved by an immediate increase of portal 
pressure from PVE. This increase of pressure may be correlated with the extent of the 
vascular bed in the embolized or remnant liver. With respect to PVE effect, pre-PVE 
portal pressure is thought to be a useful predictor.  
Serum hyaluronic acid level correlates well with degree of fibrosis or impaired 
endothelial cell function in non-parenchymal liver cells [38, 39]. Our previous study 
showed that hyaluronic acid level was an independent predictive marker for postoperative 
complications such as uncontrolled ascites or hepatic failure [22]. This morbidity may be 
affected by potential liver function. Yachida et al. [39] also reported that hyaluronic acid 
level is a good predictor of amount of hypertrophy of the non-embolized lobe. Serum 
hyaluronic acid level also reflects endothelial cell damage of hepatic sinusoids by stress. 
[40] Therefore, sinusoidal damage from PVE may affect the decrease of liver volume in 
the embolized lobe.  
ICGR15 and total bilirubin level are widely known functional parameters of the liver 
and are the most reliable tests to predict postoperative outcome [1, 4, 12, 18, 41]. In the 
present study, these parameters were correlated with the volume decrease in the 
embolized lobe.  
As in our previous study concerning morphological liver volume [11], ALP level was 
negatively correlated with embolized liver volume. Increased ALP level might reflect 
tumor or hepatic damage due to tumor location [42, 43]. Furthermore, ALP is a 
prognostic marker of liver failure after hepatectomy [44]. Since hepatic tumors are 
predominantly located in the embolized lobe, hepatic cellular damage might be 
accelerated by portal embolization. However, recognition of this parameter as a specific 
predictor may be difficult because the mechanism is unknown.  
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In any case, the present results suggest that many sensitive markers could be useful to 
predict functional atrophy of the embolized liver. 
We found fewer parameters related to increased volume in the non-embolized liver 
than to decreased volume in the embolized liver. This result could suggest that no 
dramatic alteration of liver function occurs by 2 weeks after PVE. Our previous report 
showed that hypertrophy of the remnant liver still progressed remarkably after 
hepatectomy in patients who underwent preoperative PVE [27]. Therefore, the 
regenerative capacity of the non-embolized liver should remain at this time after PVE. 
However, PVE may impede regeneration immediately after hepatectomy and thereby 
help overcome hepatic failure. The mechanism of hypertrophy of the left lobe might 
differ between PVE and hepatectomy [32]. Atrophy of the embolized lobe is thought to 
result from apoptosis [45], and because the hepatic parenchyma and its hepatic function 
remain after PVE, the extent of hypertrophy may be limited when compared with after 
hepatectomy. Unlike the non-embolized liver, the embolized liver may incur a great 
functional loss by embolization.  
Platelet count also reflects the severity of liver injury in patients with chronic viral 
hepatitis [30]. Murata et al. reported that platelets promote liver regeneration in the early 
period in a murine model [46]. Furthermore, Alkozai et al. reported that a low platelet 
count immediately after partial hepatectomy  was associated with delayed recovery of 
liver function [47]. Based on these results, platelet count appears to be a sensitive marker 
with respect to liver regeneration or functional recovery after liver stress or injury. 
Therefore, parameter alone would be useful to predict regeneration of the remnant liver 
after PVE. 
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Because PVE can also potentially induce adverse effects such liver failure, 
thrombosis, intraabdominal bleeding, or cancer progression [48], the procedure should be 
avoided in patients who are predicted to have an inadequate effect. A predictive scoring 
system for changes in hepatic volume from PVE is desirable to evaluate the effect and to 
determine the indications of this procedure. To our knowledge, few previous studies have 
reported a systematic analysis using such predictors [17]. The present study is a 
preliminary trial, due to the small number of subjects and the heterogeneous patient 
background. Our next step is to attempt to design a scoring system in larger subject group, 
using the candidate parameters clarified in the present study. Furthermore, determining 
the relationship between prediction of PVE effect or measuring functional volume, and 
post-hepatectomy liver functions or outcomes will be necessary in order to clarify the 
clinical benefit of resectability. 
In conclusion, we have reported the changes in hepatic volume measured by CT and 
RI with 99mTc-GSA liver scintigraphy before and after portal vein embolization in patients 
scheduled for extensive hepatectomy. A correlation between CT and RI volume 
parameters was observed; however, this correlation decreased after PVE. Although few 
parameters were correlated with changes of CT volume after PVE, more parameters 
(portal pressure; ICGR15; serum levels of hyaluronate, bilirubin, albumin, and ALP; and 
platelet count) were significantly correlated with changes of RI volume. Based on the 
preliminary data in the present results, these parameters are useful predictors of 
functional PVE effect and a predictive scoring system should be established in future 
studies. 
Revised-May 5-Nanashima et al., Page 18  
Figure legend 
 
FIG 1. Three dimensional measurement of CT volume (a) and RI volume (b) in the right 
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(b) 
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TABLE 1     Relationship between Changes in Hepatic Volume after Portal Vein 
Embolization and Clinicopathological Parameters 










   Male (n=15) 
   Female (n=9) 
Background liver 
   Normal (n=12) 
   Chronic viral hepatitis (n=3) 
   Cirrhosis (n=2) 
   Obstructive jaundice (n=7) 
 Embolization substance  
   Sponge powder + thrombin (n=7) 
   Lipiodol + Sponzel (n=5) 

















































Data are mean±SD 
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TABLE 2 Correlation between Parameters and Changes in CT Volume Parameter after 
Portal Vein Embolization 


















 γ  γ  
Age 
Pre-PVE portal pressure (mmHg) 
Post-PVE portal pressure (mmHg) 




Total bilirubin (mg/dl) 
Alanine aminotransferase (IU/l) 
Prothrombin activity (%) 
Platelet count (/mm3) 
Albumin (g/dl) 
Alkaline phosphatase (IU/l) 


























































ICG; indocyanine green 
LHL15; liver uptake ratio at 15 minutes by 99mTc-GSA liver scintigraphy 
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TABLE 3 Correlation between Parameters and Changes in RI Volume Parameter after 
Portal Vein Embolization 
















 γ  γ  
Age 
Pre-PVE portal pressure (mmHg) 
Post-PVE portal pressure (mmHg) 




Total bilirubin (mg/dl) 
Alanine aminotransferase (IU/l) 
Prothrombin activity (%) 
Platelet count (/mm3) 
Albumin (g/dl) 
Alkaline phosphatase (IU/l) 


























































ICG, LHL15; see in Table2 
 
